Studies on Pharmacokinetic Drug Interaction Potential of Vinpocetine

• Published in: Medicines (Basel, Switzerland) Switzerland), 2015-06, Vol.2 (2), p.93-105
• Main Authors: Manda, Vamshi K, Bharathi Avula, Olivia R. Dale, Amar G. Chittiboyina, Ikhlas A. Khan, Larry A. Walker, Shabana I. Khan
• Format: Article
• Language: English
• Subjects: adverse effects; alkaloids; biochemical pathways; central nervous system; cytochrome P-450; dietary supplements; drug interactions; drugs; enzyme inhibition; enzymes; human cell lines; humans; P-glycoproteins; pharmacokinetics; reporter genes; risk
• ISSN: 2305-6320; 2305-6320
• DOI: 10.3390/medicines2020093

Vinpocetine, a semi-synthetic derivative of vincamine, is a popular dietary supplement used for the treatment of several central nervous system related disorders. Despite its wide use, no pharmacokinetic drug interaction studies are reported in literature. Due to increasing use of dietary supplements in combination with conventional drugs, the risk of adverse effects is on the rise. As a preliminary step to predict a possibility of drug interaction during concomitant use of vinpocetine and conventional drugs, this study was carried out to evaluate the effects of vinpocetine on three main regulators of pharmacokinetic drug interactions namely, cytochromes P450 (CYPs), P-glycoprotein (P-gp), and Pregnane X receptor (PXR). Methods: Inhibition of CYPs was evaluated by employing recombinant enzymes. The inhibition of P-gp was determined by calcein-AM uptake method in transfected and wild type MDCKII cells. Modulation of PXR activity was monitored through a reporter gene assay in HepG2 cells. Results: Vinpocetine showed a strong inhibition of P-gp (EC(50) 8 µM) and a moderate inhibition of recombinant CYP3A4 and CYP2D6 (IC(50) 2.8 and 6.5 µM) with no activity towards CYP2C9, CYP2C19 and CYP1A2 enzymes. In HLM, competitive inhibition of CYP3A4 (IC(50) 54 and Ki 19 µM) and non-competitive inhibition of CYP2D6 (IC(50) 19 and Ki 26 µM) was observed. Activation of PXR was observed only at the highest tested concentration of vinpocetine (30 µM) while lower doses were ineffective. Conclusion: Strong inhibition of P-gp by vinpocetine is indicative of a possibility of drug interactions by altering the pharmacokinetics of drugs which are the substrates of P-gp. However the effects on CYPs and PXR indicate that vinpocetine may not affect CYP-mediated metabolism of drugs as the inhibitory concentrations are much greater than the expected plasma concentrations in humans.